Skip to main content
OpenTrials
Completed

NCT Number: NCT04634188

Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study

This study is a case controlled analytical study that analyzes the relationship between levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then categorized according to the variables above and analyzing to measure its significance

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Faculty of Medicine Universitas Sumatera Utara

Medan, North Sumatera, 20155, Indonesia

About this study

This study is a case controlled analytical study to find the relationship between levels of inflammatory markers in patients with brain tumors. Samples were collected from patients at Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for these variables. Sample collection began in March - September 2020. The sample obtained was 35 people who met the inclusion and exclusion criteria.

Inclusion criteria

  • Willing to be a sample
  • Complete medical records
  • Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor

Exclusion criteria

  • The patient's age is over 70 years
  • Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others
  • Patients with a history of brain tumor surgery or previous brain tumor treatment

Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically.

Based on this analysis, it will be determined whether there is a significant relationship between levels of inflammatory markers in the incidence of brain tumors.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to be a sample
  • Complete medical records
  • Head scan and head contrast MRI have been performed to confirm the patient's diagnosis with a brain tumor

Exclusion criteria

  • The patient's age is over 70 years
  • Patients with high comorbidities such as kidney failure, heart disease, diabetes, and others
  • Patients with a history of brain tumor surgery or previous brain tumor treatment

Treatment and study plan

procalcitonin

Diagnostic Test

Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically

Other names: C-Reactive Protein (CRP), Neutrophyl to Lymphocyte Ratio (NLR)

Primary outcomes

  1. Value of Procalcitonin

    Time frame: February-April 2020

    Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group)

  2. Value of C-Reactive Protein

    Time frame: April- June 2020

    Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group)

  3. Value of Neutrophyl to Lymphocyte Ratio (NLR)

    Time frame: June- August 2020

    Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group)

Secondary outcomes

  1. Demographic of samples

    Time frame: August- October 2020

    Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score

Sponsors and collaborators

Lead sponsor

Universitas Sumatera Utara

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Nov 18, 2020
Registry last updated
Nov 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.